Delving into the Latest Updates on KG2032 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target

HLA-DRB1

Action

modulators

Mechanism

HLA-DRB1 modulators(major histocompatibility complex, class II, DR beta 1 modulators)

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Acute Myeloid Leukemia

Inactive Indication-

Originator Organization

Osaka University

Active Organization

Osaka University

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Ueda, Tomoaki ; Kida, Shuhei ; Eguchi, Hidetoshi ; Ichii, Michiko ; Yoshihara, Kyoko ; Uehara, Hirofumi ; Kishima, Haruhiko ; Kogue, Yosuke ; Kawamoto, Ryuhei ; Kimura, Toru ; Kusakabe, Shinsuke ; Hino, Masayuki ; Oji, Yusuke ; Tachi, Tetsuro ; Suga, Makiko ; Inada, Yuri ; Hiroshima, Takashi ; Igashira, Eri ; Hino, Akihisa ; Kuroda, Hideki ; Tsutsumi, Kazuhito ; Yusa, Kosuke ; Fujita, Jiro ; Ikeda, Shunya ; Takeda, Kiyoshi ; Hosen, Naoki ; Yoshihara, Satoshi ; Hasegawa, Kana ; Hirose, Asao ; Shintani, Yasushi ; Nakao, Takafumi ; Ueda, Shuji ; Inoue, Megumu ; Kijima, Noriyuki ; Tachikawa, Mana ; Wibowo, Tansri ; Murakami, Koki ; Matsubara, Miwa ; Murakami, Mari ; Imai, Chihaya ; Fukushima, Kentaro ; Takagi, Junichi ; Yaga, Moto ; Ogino, Takayuki ; Arimori, Takao ; Nakamae, Hirohisa ; Shibata, Kumi ; Kumanogoh, Atsushi ; Takiuchi, Tsuyoshi ; Mori, Ryota ; Kimura, Tadashi

Acute myeloid leukemia (AML)-specific target antigens are difficult to identify. Here we demonstrate that HLA-DRB1 can serve as a leukemia-specific target of chimeric antigen receptor (CAR) T cells in patients with AML after allogeneic hematopoietic stem cell transplantation (allo-HCT). We identified KG2032 as a monoclonal antibody specifically bound to AML cells in about half of patients, but not to normal leukocytes other than B lymphocytes. KG2032 reacted with a subset of HLA-DRB1 molecules, specifically those in which the 86th amino acid was not aspartic acid. KG2032 reacted minimally with nonhematopoietic tissues. These results indicate that KG2032 reactivity is highly specific for AML cells in patients who carry KG2032-reactive HLA-DRB1 alleles and who received allo-HCT from a donor carrying KG2032-nonreactive HLA-DRB1 alleles. KG2032-derived CAR T or natural killer cells showed significant anti-leukemic activity in preclinical models in female mice, suggesting that they may cure patients with AML who are incurable with allo-HCT.

100 Deals associated with KG2032

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Preclinical	Japan	Osaka University	24 Mar 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data